A Review on Colon-Specific Drug Delivery Systems (CDDS)

Abstract

Colon-specific drug delivery systems (CDDS) have appeared as a talented possibility for the directed management of various gastrointestinal diseases and systemic conditions. This review aims to provide a comprehensive overview of CDDS, their design principles, advantages, challenges, and recent advancements. In this context, CDDS offer a solution by delivering therapeutic agents specifically to the colon, minimizing systemic exposure, reducing side effects, and enhancing therapeutic outcomes. This review delves into the various strategies employed in the development of CDDS, including pH-dependent systems, time-controlled release, and colonic prodrugs. It also discusses the formulation approaches, materials, and technologies that enable precise drug targeting to the colon. Mesalamine & Budesonide are the available drug for Colon specific drug delivery system. Additionally, this review explores the clinical relevance of CDDS, highlighting their potential in improving patient compliance, reducing dosing frequency, and enhancing the bioavailability of poorly soluble drugs. It also examines the challenges and limitations in the field, such as inter-individual variations in colon physiology, safety concerns, and regulatory issues. The role of personalized medicine and the potential impact of CDDS on the treatment of specific diseases are also discussed. CDDS come with limitations related to variability in transit times, precision, patient variability, and formulation challenges. However, further research is necessary to overcome existing challenges and ensure the safety and efficacy of these systems. This review attends as a respected reserve for researchers, clinicians, and pharmaceutical professionals seeking a deeper understanding of CDDS and their potential applications in modern healthcare.